Enanta Pharmaceuticals Competitors

Arena Pharmaceuticals (NASDAQ:ARNA) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

89.7% of Arena Pharmaceuticals shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 3.1% of Arena Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Arena Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Arena Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.

Arena Pharmaceuticals currently has a consensus price target of $92.80, indicating a potential upside of 40.82%. Enanta Pharmaceuticals has a consensus price target of $65.2857, indicating a potential upside of 28.82%. Given Arena Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Arena Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares Arena Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Arena Pharmaceuticals and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Arena Pharmaceuticals has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Enanta Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Agios Pharmaceuticals (NASDAQ:AGIO) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Agios Pharmaceuticals and Enanta Pharmaceuticals' top-line revenue, earnings per share and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Agios Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Insider and Institutional Ownership

92.9% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. 3.2% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Agios Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Agios Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Agios Pharmaceuticals presently has a consensus target price of $64.6364, suggesting a potential upside of 18.19%. Enanta Pharmaceuticals has a consensus target price of $65.2857, suggesting a potential upside of 28.82%. Given Enanta Pharmaceuticals' higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Summary

Enanta Pharmaceuticals beats Agios Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Enanta Pharmaceuticals (NASDAQ:ENTA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Enanta Pharmaceuticals and Atea Pharmaceuticals, as provided by MarketBeat.com.

Enanta Pharmaceuticals presently has a consensus price target of $65.2857, suggesting a potential upside of 28.82%. Atea Pharmaceuticals has a consensus price target of $69.3333, suggesting a potential upside of 54.28%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Enanta Pharmaceuticals and Atea Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Atea Pharmaceuticals has lower revenue, but higher earnings than Enanta Pharmaceuticals.

Insider and Institutional Ownership

90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Enanta Pharmaceuticals and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Atea Pharmaceuticals beats Enanta Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Volatility & Risk

Apellis Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Institutional and Insider Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Apellis Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Apellis Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Apellis Pharmaceuticals currently has a consensus price target of $125.00, suggesting a potential upside of 174.30%. Enanta Pharmaceuticals has a consensus price target of $65.2857, suggesting a potential upside of 28.82%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Apellis Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Turning Point Therapeutics (NASDAQ:TPTX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Turning Point Therapeutics and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Turning Point Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Insider and Institutional Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Turning Point Therapeutics and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Turning Point Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Turning Point Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Turning Point Therapeutics and Enanta Pharmaceuticals, as reported by MarketBeat.

Turning Point Therapeutics presently has a consensus target price of $153.7143, indicating a potential upside of 110.48%. Enanta Pharmaceuticals has a consensus target price of $65.2857, indicating a potential upside of 28.82%. Given Turning Point Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Turning Point Therapeutics is more favorable than Enanta Pharmaceuticals.

Summary

Turning Point Therapeutics beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Nektar Therapeutics and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Nektar Therapeutics currently has a consensus price target of $25.2857, indicating a potential upside of 33.08%. Enanta Pharmaceuticals has a consensus price target of $65.2857, indicating a potential upside of 28.82%. Given Nektar Therapeutics' higher probable upside, equities research analysts plainly believe Nektar Therapeutics is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Nektar Therapeutics and Enanta Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.3% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Nektar Therapeutics and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

Nektar Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Summary

Enanta Pharmaceuticals beats Nektar Therapeutics on 9 of the 14 factors compared between the two stocks.